Particularly, SMARCA4 variants, including both germline (43%) and somatic (57%) mutations, have been implicated as causative genetic alterations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (12). This evidence concerns the gene SMARCA4 and ovarian small cell carcinoma.